409 related articles for article (PubMed ID: 27843295)
1. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
Shen Z; Rowlings C; Kerr B; Hingorani V; Manhard K; Quart B; Yeh LT; Storgard C
Drug Des Devel Ther; 2015; 9():3423-34. PubMed ID: 26170627
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
[TBL] [Abstract][Full Text] [Related]
4. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
[TBL] [Abstract][Full Text] [Related]
5. Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor.
Shen Z; Lee CA; Valdez S; Yang X; Wilson DM; Flanagan T; Gillen M
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):647-656. PubMed ID: 30748125
[TBL] [Abstract][Full Text] [Related]
6. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Terkeltaub R; Saag KG; Goldfarb DS; Baumgartner S; Schechter BM; Valiyil R; Jalal D; Pillinger M; White WB
Rheumatology (Oxford); 2019 Jan; 58(1):61-69. PubMed ID: 30124941
[TBL] [Abstract][Full Text] [Related]
7. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
8. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
Shen Z; Tieu K; Wilson D; Bucci G; Gillen M; Lee C; Kerr B
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):377-387. PubMed ID: 28074640
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
[TBL] [Abstract][Full Text] [Related]
11. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
Tausche AK; Alten R; Dalbeth N; Kopicko J; Fung M; Adler S; Bhakta N; Storgard C; Baumgartner S; Saag K
Rheumatology (Oxford); 2017 Dec; 56(12):2170-2178. PubMed ID: 29029210
[TBL] [Abstract][Full Text] [Related]
12. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
[TBL] [Abstract][Full Text] [Related]
13. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
Saag KG; Fitz-Patrick D; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; Becker MA
Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
[TBL] [Abstract][Full Text] [Related]
14. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.
Perez-Ruiz F; Sundy JS; Miner JN; Cravets M; Storgard C;
Ann Rheum Dis; 2016 Jun; 75(6):1074-80. PubMed ID: 26742777
[TBL] [Abstract][Full Text] [Related]
15. Lesinurad: A Novel Agent for Management of Chronic Gout.
Haber SL; Fente G; Fenton SN; Walker EP; Weaver BM; Cano AJ; Vu K
Ann Pharmacother; 2018 Jul; 52(7):690-696. PubMed ID: 29482353
[TBL] [Abstract][Full Text] [Related]
16. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Dalbeth N; Jones G; Terkeltaub R; Khanna D; Kopicko J; Bhakta N; Adler S; Fung M; Storgard C; Baumgartner S; Perez-Ruiz F
Arthritis Rheumatol; 2017 Sep; 69(9):1903-1913. PubMed ID: 28597604
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
[TBL] [Abstract][Full Text] [Related]
19. New urate-lowing therapies.
Abhishek A
Curr Opin Rheumatol; 2018 Mar; 30(2):177-182. PubMed ID: 29251661
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2019 Jul; 57(7):345-352. PubMed ID: 30990408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
